摘要
新一代免疫抑制剂FK50 6(Tacrolimus)具有免疫抑制作用强 ,用药剂量少 ,毒副作用少等特点。在角膜移植实验研究中能有效防止排斥反应发生并使同种移植排斥反应逆转。
FK506 is a new type immunosuppressive agent who has greater efficacy, less dosage and lower toxicities. It is proved in experimental corneal transplantaion researches that FK506 can prevent rejection effectively and reverse ongoing rejection. [
出处
《暨南大学学报(自然科学与医学版)》
CAS
CSCD
2000年第6期117-120,共4页
Journal of Jinan University(Natural Science & Medicine Edition)